Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI115 in Advanced Small Cell Lung Cancer
NCT07559019Phase 1Recruiting
- Sponsor
- Innovent Biologics
- Start
- May 2026
- Primary completion
- Feb 2028
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of IBI115 in small cell lung cancer (SCLC), sponsored by Innovent Biologics. Primary endpoints: Number of participants with Adverse Events, Serious Adverse Events and treatment emergent adverse events, Dose-limiting toxicity and 4 more. Started May 2026; status: recruiting.
02
Drugs
IBI115
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT07559019.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07559019.